Vigonvita Life Sciences Launches HK$598 Million Hong Kong IPO

MT Newswires Live

Oct 28

Vigonvita Life Sciences (HKG:2630) launched its initial public offering in Hong Kong that seeks to raise as much as HK$598.3 million.

The biopharmaceutical company is offering 17,597,800 shares at HK$32 to HK$34 apiece.

The issuer expects to determine its final offer price on Nov. 4 and disclose the allocations on Nov. 5. It will then start trading on the Hong Kong bourse on Nov. 6, according to a Tuesday filing.

Proceeds from the deal will be used to fund clinical trials, research and development of product candidates, and construction of the company's Qingdao facility.

CLSA, China International Capital, ABCI Securities, China Galaxy International Securities (Hong Kong), CCB International Capital, China Everbright Securities (HK), Futu Securities International (Hong Kong), Tiger Brokers (HK) Global, and Zhongtai International Securities are the joint bookrunners of the IPO.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2578784601"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2578784601\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2578784601?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-28 10:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2578784601","market":"fut","top_or_hot":-1,"title":"Vigonvita Life Sciences Launches HK$598 Million Hong Kong IPO","media":"MT Newswires Live","content":"<html><body><p> Vigonvita Life Sciences (HKG:2630) launched its initial public offering in Hong Kong that seeks to raise as much as HK$598.3 million.</p><p>The biopharmaceutical company is offering 17,597,800 shares at HK$32 to HK$34 apiece.</p><p>The issuer expects to determine its final offer price on Nov. 4 and disclose the allocations on Nov. 5. It will then start trading on the Hong Kong bourse on Nov. 6, according to a Tuesday filing.</p><p>Proceeds from the deal will be used to fund clinical trials, research and development of product candidates, and construction of the company's Qingdao facility.</p><p>CLSA, China International Capital, ABCI Securities, China Galaxy International Securities (Hong Kong), CCB International Capital, China <a href=\"https://laohu8.com/S/601788\">Everbright Securities</a> (HK), Futu Securities International (Hong Kong), Tiger Brokers (HK) Global, and Zhongtai International Securities are the joint bookrunners of the IPO.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vigonvita Life Sciences Launches HK$598 Million Hong Kong IPO</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVigonvita Life Sciences Launches HK$598 Million Hong Kong IPO\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-10-28 10:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Vigonvita Life Sciences (HKG:2630) launched its initial public offering in Hong Kong that seeks to raise as much as HK$598.3 million.</p><p>The biopharmaceutical company is offering 17,597,800 shares at HK$32 to HK$34 apiece.</p><p>The issuer expects to determine its final offer price on Nov. 4 and disclose the allocations on Nov. 5. It will then start trading on the Hong Kong bourse on Nov. 6, according to a Tuesday filing.</p><p>Proceeds from the deal will be used to fund clinical trials, research and development of product candidates, and construction of the company's Qingdao facility.</p><p>CLSA, China International Capital, ABCI Securities, China Galaxy International Securities (Hong Kong), CCB International Capital, China <a href=\"https://laohu8.com/S/601788\">Everbright Securities</a> (HK), Futu Securities International (Hong Kong), Tiger Brokers (HK) Global, and Zhongtai International Securities are the joint bookrunners of the IPO.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0441854154.USD","symbol_name":"JPM ASIA PACIFIC EQUITY \"A\" (USD) ACC","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2578784601","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2578784601","pubTimestamp":1761617459,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Vigonvita Life Sciences  launched its initial public offering in Hong Kong that seeks to raise as much as HK$598.3 million.The biopharmaceutical company is offering 17,597,800 shares at HK$32 to HK$34 apiece.The issuer expects to determine its final offer price on Nov. 4 and disclose the allocations on Nov. 5. It will then start trading on the Hong Kong bourse on Nov. 6, according to a Tuesday filing.Proceeds from the deal will be used to fund clinical trials, research and development of product candidates, and construction of the company's Qingdao facility.CLSA, China International Capital, ABCI Securities, China Galaxy International Securities , CCB International Capital, China Everbright Securities , Futu Securities International , Tiger Brokers  Global, and Zhongtai International Securities are the joint bookrunners of the IPO.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0441854154.USD":"JPM ASIA PACIFIC EQUITY \"A\" (USD) ACC","03143":"华夏香港银行股","IE00B19Z5X02.USD":"Legg Mason QS - MV Asia Pacific ex Japan Equity Growth and Income A Acc USD","IE00BPRC5H50.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) INC","00939":"建设银行","LU0264606111.USD":"Janus Henderson Horizon Asian Dividend Income A2 USD","LU0293314216.USD":"ALLIANZ GEM EQUITY HIGH DIVIDEND \"A\" (USD) ACC","LU0633140560.USD":"AB EMERGING MARKET MULTI ASSET PORTFOLIO \"A\" (USD) ACC","LU2226246903.HKD":"ALLIANZ TOTAL RETURN ASIAN EQUITY \"AT4\" (HKD) ACC","LU1880383366.USD":"东方汇理中国股票基金 A2 (C)","LU0359201612.USD":"贝莱德中国基金A2","SG9999014674.SGD":"Nikko AM All China Equity A SGD","LU1224709979.USD":"FIDELITY CHINA FOCUS \"A\" (USD) ACC","LU0359202008.SGD":"Blackrock China Fund A2 SGD-H","LU0096374516.USD":"CT (LUX) I ASIA EQUITY INCOME \"DU\" (USD) ACC","LU0370786039.SGD":"Fidelity Greater China A-SGD","LU1770036033.HKD":"NINETY ONE GSF ASIAN EQUITY \"A\" (HKD) ACC","02630":"旺山旺水-B","LU1023057109.AUD":"BGF CHINA \"A2\" (AUDHDG) ACC","LU0683595622.HKD":"AB SICAV I-EM.MKTS MUL.ASS.PTF(AD)","LU1808992512.USD":"AB ALL CHINA EQUITY PORTFOLIO \"A\" (USD) ACC","LU0572944931.SGD":"Janus Henderson Horizon China Opportunities A2 SGD","IE00B543WZ88.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) ACC","LU0326950275.SGD":"Schroder ISF China Opportunities A Acc SGD-H","LU0633140727.USD":"AB EMERGING MARKETS MULTI ASSET PORTFOLIO \"AD\" (USD) INC","LU1504937902.USD":"CT (LUX) I ASIAN EQUITY INCOME \"DUP\" (EUR) INC","LU1831875114.USD":"SCHRODER ISF ALL CHINA EQUITY \"A\" (USD) ACC","LU0572939691.SGD":"Janus Henderson Horizon Asian Dividend Income A2 SGD","LU0516423091.SGD":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"I\" (SGD) ACC","LU1105468828.SGD":"Allianz Total Return Asian Equity AM DIS H2-SGD","SG9999013353.USD":"SCHRODER ASIAN INCOME FUND\"A\" (USDHDG) INC","LU0320764599.SGD":"FTIF - Templeton China A Acc SGD","LU1568876335.HKD":"ALLIANZ CHINA MULTI INCOME PLUS \"AMG\" (HKD) INC","LU1770034418.SGD":"ALL CHINA EQUITY \"A\" (SGDHDG) ACC","LU0431992006.USD":"摩根大通新兴市场机会A（acc）","LU0918141705.HKD":"ALLIANZ TOTAL RETURN ASIAN EQUITY \"AM\" (HKD) INC","LU1794554557.SGD":"Allianz All China Equity AT Acc H2-SGD","LU0348814723.USD":"ALLIANZ TOTAL RETURN ASIAN EQUITY \"A\" (USD) INC  NC","LU1568876251.USD":"ALLIANZ CHINA MULTI INCOME PLUS \"AMG\" (USD) INC","IE00B5MMRT66.SGD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (SGDHDG) ACC","LU1282648689.USD":"ALLIANZ TOTAL RETURN ASIAN EQUITY \"AMG\" (USD) INC","LU1813983027.USD":"MANULIFE GF DRAGON GROWTH \"AA\" (USD) INC","LU1044875133.USD":"天利亚洲反向股票 AU Acc","LU1242518857.USD":"FULLERTON LUX FUNDS - ASIA ABSOLUTE ALPHA \"I\" (USD) ACC","LU0287142896.SGD":"Fidelity China Focus A-SGD","LU0823039010.USD":"AMUNDI FUNDS ASIA EQUITY FOCUS  \"A2\" (USD) INC","LU0359201885.HKD":"BGF CHINA \"A2\" (HKD) ACC","LU0675040207.SGD":"JPM ASIA PACIFIC EQUITY \"A\" (SGD) ACC","LU0211977185.USD":"EASTSPRING INVESTMENTS GREATER CHINA EQUITY \"A\" ACC","LU0396098781.USD":"ALLIANZ CHINA MULTI INCOME PLUS \"AT\" (USD) ACC"},"translate_title":"Vigonvita生命科学5.98亿港元香港IPO","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00939":0.75,"02630":0.9,"03143":0.6},"content_text":"Vigonvita Life Sciences (HKG:2630) launched its initial public offering in Hong Kong that seeks to raise as much as HK$598.3 million.The biopharmaceutical company is offering 17,597,800 shares at HK$32 to HK$34 apiece.The issuer expects to determine its final offer price on Nov. 4 and disclose the allocations on Nov. 5. It will then start trading on the Hong Kong bourse on Nov. 6, according to a Tuesday filing.Proceeds from the deal will be used to fund clinical trials, research and development of product candidates, and construction of the company's Qingdao facility.CLSA, China International Capital, ABCI Securities, China Galaxy International Securities (Hong Kong), CCB International Capital, China Everbright Securities (HK), Futu Securities International (Hong Kong), Tiger Brokers (HK) Global, and Zhongtai International Securities are the joint bookrunners of the IPO.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}